Related Experiment Videos
[Ovarian neoplasms and tumor markers]
R Zarcone1, R Candido, G Cardone
1Facoltà di Medicina e Chirurgia, II Cattedra di Ginecologia ed Ostetrica, II Università degli Studi di Napoli.
Minerva Ginecologica
|October 1, 1994
Summary
The CA125 biomarker is useful for monitoring ovarian cancer treatment response. Declining CA125 levels correlate with tumor shrinkage, while stable or rising levels indicate treatment resistance.
Area of Science:
- Oncology
- Biochemistry
Background:
- Ovarian cancer management requires reliable biomarkers for treatment monitoring.
- CA125 is a commonly used tumor marker in ovarian cancer.
Purpose of the Study:
- To evaluate the utility of CA125 in assessing ovarian cancer diagnosis, staging, prognosis, and response to therapy.
- To correlate CA125 levels with treatment outcomes in epithelial ovarian cancer patients.
Main Methods:
- Quantitative CA125 testing using monoclonal antibody OC125.
- Testing performed pre- and post-antineoplastic treatment in 21 ovarian cancer patients (ages 38-66).
- Analysis of CA125 level changes in relation to neoplastic regression, stasis, or non-responsiveness.
Main Results:
- A reduction in CA125 levels was associated with neoplastic regression.
- Persistent or increasing CA125 values correlated with neoplastic stasis or non-responsive neoplasia.
- The CA125 assay demonstrated specificity but had lower sensitivity for detecting minimal residual disease.
Conclusions:
- CA125 monitoring is valuable for assessing therapeutic response in ovarian cancer.
- Changes in CA125 levels can indicate treatment effectiveness or resistance.
- The sensitivity limitations of CA125 for minimal residual disease should be considered.